Valuation: Fulgent Genetics, Inc.

Capitalization 87Cr 75Cr 69Cr 65Cr 120.32Cr 7.89TCr 129.3Cr 799.25Cr 314.79Cr 3.76TCr 325.52Cr 318.84Cr 14TCr P/E ratio 2025 *
-19.2x
P/E ratio 2026 * -16.8x
Enterprise value 7.28Cr 6.26Cr 5.81Cr 5.42Cr 10Cr 661.95Cr 11Cr 67Cr 26Cr 315.17Cr 27Cr 27Cr 1.15TCr EV / Sales 2025 *
0.22x
EV / Sales 2026 * 0.25x
Free-Float
62.05%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.99%
1 week+0.83%
Current month+6.89%
1 month+0.07%
3 months+23.81%
6 months+57.93%
Current year+6.89%
More quotes
1 week 27.39
Extreme 27.39
28.95
1 month 25.07
Extreme 25.07
28.95
Current year 25.07
Extreme 25.07
28.95
1 year 14.57
Extreme 14.57
31.04
3 years 14.57
Extreme 14.57
44.09
5 years 14.57
Extreme 14.57
189.89
10 years 2.72
Extreme 2.725
189.89
More quotes
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.99%+0.83%+64.21%-15.27% 87Cr
-3.78%-1.31%+46.03%+464.30% 3.2TCr
-0.77%+2.99%-16.50%-26.46% 767.76Cr
-2.74%-9.22%+18.59%+252.13% 548.63Cr
-1.10%-20.17%+55.56%+624.59% 312.4Cr
-1.04%+0.17%-1.90%+30.00% 257.45Cr
-12.86%+16.34%+137.50%-5.39% 221.62Cr
-0.12%-3.27%+26.05%-61.01% 216.73Cr
0.00%+2.50% - - 180.66Cr
-0.31%-2.81%-9.99%+8.30% 165.49Cr
Average -2.47%-3.95%+35.50%+141.24% 595.62Cr
Weighted average by Cap. -3.00%-2.62%+34.92%+310.21%
See all sector performances

Financials

2025 *2026 *
Net sales 32Cr 28Cr 26Cr 24Cr 45Cr 2.95TCr 48Cr 298.84Cr 117.7Cr 1.4TCr 121.71Cr 119.21Cr 5.13TCr 36Cr 31Cr 28Cr 27Cr 49Cr 3.24TCr 53Cr 328.07Cr 129.21Cr 1.54TCr 133.62Cr 130.87Cr 5.63TCr
Net income -4.9Cr -4.21Cr -3.9Cr -3.65Cr -6.79Cr -445.08Cr -7.3Cr -45Cr -18Cr -211.91Cr -18Cr -18Cr -774.4Cr -6.16Cr -5.29Cr -4.91Cr -4.59Cr -8.54Cr -559.62Cr -9.17Cr -57Cr -22Cr -266.44Cr -23Cr -23Cr -973.68Cr
Net Debt -80Cr -68Cr -63Cr -59Cr -110.23Cr -7.23TCr -118.45Cr -732.18Cr -288.37Cr -3.44TCr -298.21Cr -292.08Cr -13TCr -78Cr -67Cr -62Cr -58Cr -107.75Cr -7.06TCr -115.78Cr -715.7Cr -281.88Cr -3.36TCr -291.5Cr -285.51Cr -12TCr
More financial data * Estimated data
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
Employees
1,313
More about the company
Date Price Change Volume
16/26/16 28.08 $ -1.99% 3,10,493
15/26/15 28.65 $ +2.43% 2,18,316
14/26/14 27.97 $ -1.38% 2,76,691
13/26/13 28.36 $ +0.71% 1,92,899
12/26/12 28.16 $ +1.11% 2,17,510

Delayed Quote Nasdaq, January 17, 2026 at 02:30 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
28.08USD
Average target price
33.67USD
Spread / Average Target
+19.90%
Consensus

Quarterly revenue - Rate of surprise